AT&T (T) stock rose Tuesday as UBS and Barclays issued upgrades ahead of the expected closing of the telecom firm’s acquisition of satellite TV broadcaster DirecTV Group. UBS analyst John Hodulik upgraded AT&T to buy and raised his price target to 42 from 34. Barclays analyst Amir Rozwadowski upgraded AT&T to overweight, raising his price target to 39 from 34. Analysts at Credit Suisse, JPMorgan and Macquarie Capital recently had issued upbeat
BlackBerry (BBRY) continues to struggle with efforts to rebuild, as its fiscal Q1 earnings posted early Tuesday missed expectations. BlackBerry reported revenue of $658 million, down 32% from the year-earlier quarter and its seventh quarter in a row of double-digit declines. The consensus estimate of analysts polled by Thomson Reuters called for sales of $682.6 million. BlackBerry reported a per-share loss minus items of 5 cents for the quarter
Just how many biotech IPOs can one market take? Investors might be asking themselves this question as the explosion of new issues in the sector shows no sign of slowing for a third straight year. RBC Capital Markets counts 29 IPOs in the sector this year through Friday — putting 2015 possibly on pace to pass 2014, when 67 biotechs debuted “in line with the previous peak in 2000,” said RBC analyst Michael Yee in a research report. Yee said that the